Groundbreaking Enrollment in the DurAVR® THV Trial
Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR), a leader in the field of structural heart devices, has made a significant advancement in treating severe aortic stenosis by initiating patient enrollment in its DurAVR® Transcatheter Heart Valve (THV) pivotal trial, known as the PARADIGM Trial. This landmark study aims to evaluate the safety and effectiveness of the DurAVR® THV compared to existing commercial options in a robust clinical framework.
Patient Treatment Commences
The first patients were successfully treated in this trial, a promising milestone for Anteris. The procedures took place at The Heart Center, Rigshospitalet, an esteemed medical facility known for its advanced cardiac care. Prof. Dr. Ole De Backer, who led the treatment, expressed immense pride in being part of the initial phase, emphasizing the positive early results with the DurAVR® THV System. The aim is to provide high-quality, comparative evidence that could significantly influence patient care in the future.
Significance of the PARADIGM Trial
The PARADIGM Trial is an essential step in advancing the treatment landscape for patients suffering from severe calcific aortic stenosis. By enrolling approximately 1,000 patients, this prospective randomized controlled trial will assess the DurAVR® THV against commercially approved transcatheter aortic valve replacements (TAVRs) on multiple fronts, including efficacy and safety. The rigorous design of the study is configured to yield high-quality evidence to support the commercial rollout of the device.
Evaluation Criteria and Methodology
In the trial, patients will be randomized 1:1 to receive either the DurAVR® THV or a conventional TAVR. The overarching goal is to demonstrate non-inferiority in a composite endpoint that includes all-cause mortality, strokes, and cardiovascular hospitalization within a year post-procedure. This meticulous approach ensures that the outcomes are measured against the highest standards in the industry, providing actionable insights for further development.
Expanding Horizons for Aortic Stenosis Treatment
Anteris is poised to expand the trial to include more sites across the United States, Europe, and Canada in the coming months. The company's leadership believes that the enthusiastic participation from various investigators will facilitate efficient recruitment and timely progress. Through this global effort, Anteris aims not only to collect critical data but also to enhance patient treatment options significantly.
About Anteris Technologies
Anteris Technologies Global Corp. is dedicated to developing innovative solutions aimed at restoring healthy heart function. Founded in Australia with key operations in Minneapolis, USA, Anteris specializes in cutting-edge medical devices, focusing on the development of the DurAVR® THV for treating aortic stenosis. The device uses FDA-cleared ADAPT® tissue technology, which has been clinically utilized for over a decade, ensuring safety and effectiveness in patient care.
Frequently Asked Questions
What is the DurAVR® THV?
The DurAVR® THV is a cutting-edge transcatheter heart valve designed to treat severe aortic stenosis, mimicking the function of a healthy aortic valve.
What is the PARADIGM Trial focusing on?
The PARADIGM Trial focuses on evaluating the safety and effectiveness of the DurAVR® THV against existing transcatheter aortic valve replacements.
How many patients will be enrolled in the trial?
Approximately 1,000 patients will be enrolled in the trial to gather comprehensive data on the DurAVR® THV's performance.
Who is leading the patient treatments for the trial?
The treatments for the trial are led by Prof. Dr. Ole De Backer at The Heart Center, Rigshospitalet.
What are the expected outcomes of the trial?
The trial is expected to provide solid evidence regarding the safety, effectiveness, and patient outcomes associated with the DurAVR® THV.
